Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers
Launched by ASTRAZENECA · Feb 27, 2009
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Regular Daily Bowel movements
- • Veins suitable for cannulation or repeated venepuncture
- Exclusion Criteria:
- • Presence of any clinically significant illness
- • Abnormal vital signs
- • History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Alderley Park, Cheshire, United Kingdom
Patients applied
Trial Officials
Raj Chetty, MD
Principal Investigator
AstraZeneca, Clinical Pharamcology Unit, Alderley Park
Mary Stuart, MD
Study Director
AstraZeneca, Parklands, Alderley Park
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials